130 related articles for article (PubMed ID: 25107463)
1. Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.
Hasegawa T; Aisa Y; Shimazaki K; Nakazato T
Ann Hematol; 2015 Mar; 94(3):515-7. PubMed ID: 25107463
[No Abstract] [Full Text] [Related]
2. Bendamustine can severely impair T-cell immunity against cytomegalovirus.
Hosoda T; Yokoyama A; Yoneda M; Yamamoto R; Ohashi K; Kagoo T; Ueno H; Boku S; Yano T
Leuk Lymphoma; 2013 Jun; 54(6):1327-8. PubMed ID: 23072371
[No Abstract] [Full Text] [Related]
3. [Development of cytomegalovirus antigenemia in 3 patients with B cell lymphoma treated with bendamustine monotherapy].
Mitsumori T; Sueki Y; Kawashima I; Yamamoto T; Nozaki Y; Nakajima K; Kirito K
Rinsho Ketsueki; 2014 Feb; 55(2):239-43. PubMed ID: 24598192
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.
Isono N; Imai Y; Watanabe A; Moriya K; Tamura H; Inokuchi K; Asano C; Masuda M; Shimura H; Mitsuhashi K; Kazama H; Sugimori H; Motoji T; Tanaka J
Leuk Lymphoma; 2016 Sep; 57(9):2204-7. PubMed ID: 26699798
[No Abstract] [Full Text] [Related]
5. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine.
Lim SH; Pathapati S; Langevin J; Hoot A
Ann Hematol; 2012 Apr; 91(4):643-4. PubMed ID: 21811782
[No Abstract] [Full Text] [Related]
6. Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.
Yamasaki S; Kohno K; Kadowaki M; Takase K; Iwasaki H
Ann Hematol; 2017 Jul; 96(7):1215-1217. PubMed ID: 28447162
[No Abstract] [Full Text] [Related]
7. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
[TBL] [Abstract][Full Text] [Related]
8. CMV Pneumonitis following Bendamustine containing Chemotherapy.
Singhania SVK; Parikh P; Goyle S
J Assoc Physicians India; 2017 Sep; 65(9):92-93. PubMed ID: 29313585
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
[TBL] [Abstract][Full Text] [Related]
10. Stevens-Johnson syndrome after treatment with bendamustine.
Lambertini M; Del Mastro L; Gardin G; Levaggi A; Bighin C; Giraudi S; Pronzato P
Leuk Res; 2012 Jul; 36(7):e153-4. PubMed ID: 22480970
[No Abstract] [Full Text] [Related]
11. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
[TBL] [Abstract][Full Text] [Related]
12. Localized cytomegalovirus reactivation after radiotherapy for high-grade gastric lymphoma.
Saga K; Fukui T; Kato Y; Komeda T; Nakase H; Watanabe N; Nishio A; Chiba T
Gastrointest Endosc; 2007 Mar; 65(3):545-7. PubMed ID: 17321266
[No Abstract] [Full Text] [Related]
13. [Recommendation for the optimal use of bendamustine in Japan].
Ohmachi K; Maruyama D; Nisikori M; Suzuki T; Izutsu K
Rinsho Ketsueki; 2014 Mar; 55(3):311-20. PubMed ID: 24681934
[No Abstract] [Full Text] [Related]
14. Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect.
Malipatil B; Ganesan P; Sundersingh S; Sagar TG
Hematol Oncol Stem Cell Ther; 2011; 4(4):157-60. PubMed ID: 22198186
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine-induced "flagellate dermatitis".
Mahmoud BH; Eide MJ
Dermatol Online J; 2012 Nov; 18(11):12. PubMed ID: 23217953
[TBL] [Abstract][Full Text] [Related]
16. Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
Meije Y; Lizasoain M; García-Reyne A; Martínez P; Rodríguez V; López-Medrano F; Juan RS; Lalueza A; Aguado JM
Clin Infect Dis; 2010 Jun; 50(12):e73-6. PubMed ID: 20455691
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus antigenemia and end-organ disease in Japanese patients treated with bendamustine.
Chiba A; Nakamura F; Nakazaki K; Kurokawa M
Leuk Lymphoma; 2018 Mar; 59(3):749-751. PubMed ID: 28697686
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.
Corazzelli G; Angrilli F; D'Arco A; Ferrara F; Musto P; Guarini A; Cox MC; Stelitano C; Storti S; Iannitto E; Falorio S; Califano C; Amore A; Arcamone M; De Filippi R; Pinto A
Br J Haematol; 2013 Jan; 160(2):207-15. PubMed ID: 23167437
[TBL] [Abstract][Full Text] [Related]
19. Fatal ongoing human cytomegalovirus reactivation during high-dose melphalan and autologous stem cell transplantation.
Focosi D; Sordi E; Papineschi F; Benedetti E; Galimberti S; Petrini M
J Med Virol; 2009 May; 81(5):857-60. PubMed ID: 19319946
[TBL] [Abstract][Full Text] [Related]
20. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
[No Abstract] [Full Text] [Related]
[Next] [New Search]
